Titrating Rituximab to Circulating B Cells to Optimize Lymphocytolytic Therapy in Idiopathic Membranous Nephropathy — Paolo Cravedi (2007) | RDL Network
Titrating Rituximab to Circulating B Cells to Optimize Lymphocytolytic Therapy in Idiopathic Membranous Nephropathy
Article 2007 en
Authors
PC
Paolo Cravedi
PR
Piero Ruggenenti
MS
Maria Chiara Sghirlanzoni
Abstract
1 min read
Avoiding unnecessary reexposure to rituximab is extremely cost-saving and may limit the production of antichimeric antibodies that may increase the risk for adverse reactions and prevent re-treatment of disease recurrences.
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.